<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:24.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Cambria","serif";
color:#365F91;
font-weight:bold;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='color:#1F497D'>Hi all:</span><o:p></o:p></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Interesting announcement, below.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>It raises the question “who will step up to the plate?”.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Take care,<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div><h1>ZYTIGA®* Now Available for Men with Metastatic Prostate Cancer in British Columbia Prior to Chemotherapy<o:p></o:p></h1><p id="yui_3_9_1_1_1385127541904_1233">TORONTO , Nov. 21, 2013 /CNW/ - Effective November 15, 2013 , British Columbia is the first province to include ZYTIGA<sup>®</sup> (abiraterone acetate) on its public formulary for men living with metastatic prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT).<sup>1</sup> Men living with advanced prostate cancer, their caregivers and health care professionals are encouraged to learn more about the specific eligibility criteria that are required to be met for reimbursement of ZYTIGA<sup>®</sup> by the B.C. Cancer Agency at the following <a href="http://www.bccancer.bc.ca/NR/rdonlyres/4478D9DB-662B-43C2-8839-6D3C374D3FAE/67240/STUpdateNov2013SupplementFinal.pdf">link</a>. <o:p></o:p></p><p id="yui_3_9_1_1_1385127541904_1234">"I support the B.C. Cancer Agency's decision to reimburse ZYTIGA<sup>®</sup> as I have seen the benefits of this treatment for men living with advanced prostate cancer," says Dr. Martin Gleave **, urologic surgeon and Executive Director, Vancouver Prostate Centre. "It's exciting to have an option now available for treatment earlier in the disease that can help delay progression and improve overall quality of life." <o:p></o:p></p><p id="yui_3_9_1_1_1385127541904_1182">In July 2011 , ZYTIGA<sup>® </sup>was approved by Health Canada for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who had received prior chemotherapy containing docetaxel after failure of ADT.<sup>2</sup> Health Canada approved a second indication for ZYTIGA<sup>®</sup> in May 2013 for the treatment of men with mCRPC who are asymptomatic or mildly symptomatic after failure of ADT.<sup>3</sup> <o:p></o:p></p><p>"The expansion of access to ZYTIGA<sup>®</sup> is welcome news for eligible men to help restrict this common and lethal disease," says Don Konantz , age 51 from Vancouver, BC . "On behalf of patients with metastatic prostate cancer and as the Chair of the Canadian Coalition to Cure Prostate Cancer, I congratulate British Columbia and the B.C. Cancer Agency for their leadership." <o:p></o:p></p><p><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><h1><span style='color:red'>Perhaps it is time for PCC to mobilize the troops across Canada to get the other provinces to follow suit. <o:p></o:p></span></h1><p><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p></div></div></body></html>